Top

Published in:

01-07-2019 | Parkinson's Disease | Neurology and Preclinical Neurological Studies - Review Article

Dyskinesia in multiple system atrophy and progressive supranuclear palsy

Authors: Wolfgang H. Jost, Paul Lingor, Lars Tönges, Johannes Schwarz, Carsten Buhmann, Jan Kassubek, Anette Schrag

Published in: Journal of Neural Transmission | Issue 7/2019

Abstract

In the differential diagnosis of Parkinson syndromes, the response to l-Dopa is an essential criterion for the diagnosis of idiopathic Parkinson’s syndrome (IPS), and the presence of l-Dopa-induced dyskinesia (LID) is considered a supportive criterion. This implies that in the presence of LID an atypical Parkinson-syndrome (APS) is unlikely. However, dyskinesia, and in particular LID, can also be present in APS such as MSA and PSP, although less frequently, and with varying clinical appearance. We conclude that whilst presence of dyskinesia provides support for a diagnosis of IPD, they do not allow reliable differentiation from APS.

Antonini A, Schwarz J, Oertel WH, Beer HF, Madeja UD, Leenders KL (1994) [11C]raclopride and positron emission tomography in previously untreated patients with Parkinson’s disease: influence of l-dopa and lisuride therapy on striatal dopamine D2-receptors. Neurology 44:1325–1329CrossRefPubMed

Antonini A, Schwarz J, Oertel WH, Pogarell O, Leenders KL (1997) Long-term changes of striatal dopamine D2 receptors in patients with Parkinson’s disease: a study with positron emission tomography and [11C]raclopride. Mov Disord 12:33–38CrossRefPubMed

Batla A, De Pablo-Fernandez E, Erro R, Reich M, Calandra-Buonaura G, Barbosa P, Balint B, Ling H, Islam S, Cortelli P, Volkmann J, Quinn N, Holton JL, Warner TT, Bhatia KP (2018) Young-onset multiple system atrophy: clinical and pathological features. Mov Disord 33:1099–1107CrossRefPubMed

Berciano J, Valldeoriola F, Ferrer I, Rumià J, Pascual J, Marín C, Rey MJ, Tolosa E (2002) Presynaptic parkinsonism in multiple system atrophy mimicking Parkinson’s disease: a clinicopathological case study. Mov Disord 17:812–816CrossRefPubMed

Birdi S, Rajput AH, Fenton M, Donat JR, Rozdilsky B, Robinson C, Macaulay R, George D (2002) Progressive supranuclear palsy diagnosis and confounding features: report on 16 autopsied cases. Mov Disord 17:1255–1264CrossRefPubMed

Blanchet PJ, Konitsiotis S, Chase TN (1998) Amantadine reduces levodopa-induced dyskinesias in Parkinsonian monkeys. Mov Disord 13:798–802CrossRefPubMed

Boesch S, Wenning GK, Ransmayr G, Poewe W (2002) Dystonia in multiple system atrophy. J Neurol Neurosurg Psych 72:300–303CrossRef

Cai DF, Chen XQ, Gao Y (2002) Effect of bushen yanggan recipe on nigrostriatal function in parkinsonian model rats after long-term levodopa treatment. Zhongguo Zhong Xi Yi Jie He Za Zhi 22:43–46PubMed

Calabresi P, Di Filippo M, Ghiglieri V, Tambasco N, Picconi B (2010) Levodopa-induced dyskinesias in patients with Parkinson’s disease: filling the bench-to-bedside gap. Lancet Neurol 9:1106–1117CrossRefPubMed

Cilia R, Akpalu A, Sarfo FS, Cham M, Amboni M, Cereda E, Fabbri M, Adjei P, Akassi J, Bonetti A, Pezzoli G (2014) The modern pre-levodopa era of Parkinson’s disease: insights into motor complications from sub-Saharan Africa. Brain 137:2731–2742CrossRefPubMedPubMedCentral

Constantinescu R, Richard I, Kurlan R (2007) Levodopa responsiveness in disorders with Parkinsonism: a review of the literature. Mov Disord 22:2141–2148CrossRefPubMed

Drucker GE, Ritzmann RF, Wichlinski LJ, Engh K, Gordon JH, Fields JZ (1994) Prevention and reversal of dopamine receptor supersensitivity by cyclo(leucyl-glycyl) (CLG): biphasic dose-response curves. Pharmacol Biochem Behav 47:141–145CrossRefPubMed

Dunah AW, Wang Y, Yasuda RP, Kameyama K, Huganir RL, Wolfe BB, Standaert DG (2000) Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-D-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson’s disease. Mol Pharmacol 57:342–352PubMed

Espay AJ, Morgante F, Merola A, Fasano A, Marsili L, Fox SH, Bezard E, Picconi B, Calabresi P, Lang AE (2018) Levodopa-induced dyskinesia in Parkinson disease: current and evolving concepts. Ann Neurol 84:797–811CrossRefPubMed

Fahn S (1999) Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA. Arch Neurol 56:529–535CrossRefPubMed

Fereshtehnejad SM, Zeighami Y, Dagher A, Postuma RB (2017) Clinical criteria for subtyping Parkinson’s disease: biomarkers and longitudinal progression. Brain 140:1959–1976CrossRefPubMed

Frosch MP (2017) Tau aggregates: where, when, why and what consequences? Neuropathol Appl Neurobiol 43:371–372CrossRefPubMed

Geurts M, Hermans E, Maloteaux JM (1999) Enhanced striatal dopamine D(2) receptor-induced [35S]GTPgammaS binding after haloperidol treatment. Eur J Pharmacol 382:119–127CrossRefPubMed

Gibb WR, Lees AJ (1988) A comparison of clinical and pathological features of young- and old-onset Parkinson’s disease. Neurology 38:1402–1406CrossRefPubMed

Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, Wood NW, Colosimo C, Durr A, Fowler CJ, Kaufmann H, Klockgether T, Lees A, Poewe W, Quinn N, Revesz T, Robertson D, Sandroni P, Seppi K, Vidailhet M (2008) Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71:670–676CrossRefPubMedPubMedCentral

Ginovart N, Farde L, Halldin C, Swahn CG (1999) Changes in striatal D2-receptor density following chronic treatment with amphetamine as assessed with PET in nonhuman primates. Synapse 31:154–162CrossRefPubMed

Höglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, Mollenhauer B, Muller U, Nilsson C, Whitwell JL, Arzberger T, Englund E, Gelpi E, Giese A, Irwin DJ, Meissner WG, Pantelyat A, Rajput A, van Swieten JC, Troakes C, Antonini A, Bhatia KP, Bordelon Y, Compta Y, Corvol JC, Colosimo C, Dickson DW, Dodel R, Ferguson L, Grossman M, Kassubek J, Krismer F, Levin J, Lorenzl S, Morris HR, Nestor P, Oertel WH, Poewe W, Rabinovici G, Rowe JB, Schellenberg GD, Seppi K, van Eimeren T, Wenning GK, Boxer AL, Golbe LI, Litvan I (2017) Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord 32:853–864CrossRefPubMedPubMedCentral

Huang Y, Garrick R, Cook R, O’Sullivan D, Morris J, Halliday GM (2005) Pallidal stimulation reduces treatment-induced dyskinesias in “minimal-change” multiple system atrophy. Mov Disord 20:1042–1047CrossRefPubMed

Kim JM, Lee KH, Choi YL, Choe GY, Jeon BS (2002) Levodopa-induced dyskinesia in an autopsy-proven case of progressive supranuclear palsy. Mov Disord 17:1089–1090CrossRefPubMed

Koga S, Dickson DW (2018) Recent advances in neuropathology, biomarkers and therapeutic approach of multiple system atrophy. J Neurol Neurosurg Psychiatry 89:175–184CrossRefPubMed

Kompoliti K, Goetz CG, Litvan I, Jellinger K, Verny M (1998) Pharmacological therapy in progressive supranuclear palsy. Arch Neurol 55:1099–1102CrossRefPubMed

Krismer F, Wenning GK (2017) Multiple system atrophy: insights into a rare and debilitating movement disorder. Nat Rev Neurol 13:232–243CrossRefPubMed

Lang AE (2005) Treatment of progressive supranuclear palsy and corticobasal degeneration. Mov Disord 20(Suppl 12):S83–S91CrossRefPubMed

Lee FJ, Xue S, Pei L, Vukusic B, Chéry N, Wang Y, Wang YT, Niznik HB, Yu XM, Liu F (2002) Dual regulation of NMDA receptor functions by direct protein–protein interactions with the dopamine D1 receptor. Cell 111:219–230CrossRefPubMed

Levin J, Kurz A, Arzberger T, Giese A, Höglinger GU (2016) The differential diagnosis and treatment of atypical Parkinsonism. Dtsch Arztebl Int 113:61–69PubMedPubMedCentral

Lim J, Yue Z (2015) Neuronal aggregates: formation, clearance, and spreading. Dev Cell 32:491–501CrossRefPubMedPubMedCentral

Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, Goetz CG, Golbe LI, Grafman J, Growdon JH, Hallett M, Jankovic J, Quinn NP, Tolosa E, Zee DS (1996) Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 47:1–9CrossRefPubMed

Litvan I, Bhatia KP, Burn DJ, Goetz CG, Lang AE, McKeith I, Quinn N, Sethi KD, Shults C, Wenning GK (2003) Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord 18:467–486CrossRefPubMed

Low PA, Reich SG, Jankovic J, Shults CW, Stern MB, Novak P, Tanner CM, Gilman S, Marshall FJ, Wooten F, Racette B, Chelimsky T, Singer W, Sletten DM, Sandroni P, Mandrekar J (2015) Natural history of multiple system atrophy in the USA: a prospective cohort study. Lancet Neurol 14:710–719CrossRefPubMedPubMedCentral

Marsden CD (1994) Problems with long-term levodopa therapy for Parkinson’s disease. Clin Neuropharmacol 17(Suppl 2):S32–S44PubMed

Meissner WG, Laurencin C, Tranchant C, Witjas T, Viallet F, Guehl D, Damier P, Houeto JL, Tison F, Eusebio A, Vital A, Streichenberger N, Lannes B, Maues de Paula A, Thobois S (2016) Outcome of deep brain stimulation in slowly progressive multiple system atrophy: a clinico-pathological series and review of the literature. Parkinsonism Relat Disord 24:69–75CrossRefPubMed

Mouradian MM, Juncos JL, Fabbrini G, Schlegel J, Bartko JJ, Chase TN (1988) Motor fluctuations in Parkinson’s disease: central pathophysiological mechanisms, Part II. Ann Neurol 24:372–378CrossRefPubMed

Mudher A, Colin M, Dujardin S, Medina M, Dewachter I, Alavi Naini SM, Mandelkow EM, Mandelkow E, Buee L, Goedert M, Brion JP (2017) What is the evidence that tau pathology spreads through prion-like propagation? Acta Neuropathol Commun 5:99CrossRefPubMedPubMedCentral

Narasimhan S, Guo JL, Changolkar L, Stieber A, McBride JD, Silva LV, He Z, Zhang B, Gathagan RJ, Trojanowski JQ, Lee VMY (2017) Pathological tau strains from human brains recapitulate the diversity of tauopathies in nontransgenic mouse brain. J Neurosci 37:11406–11423CrossRefPubMedPubMedCentral

Nieforth KA, Golbe LI (1993) Retrospective study of drug response in 87 patients with progressive supranuclear palsy. Clin Neuropharmacol 16:338–346CrossRefPubMed

Nutt JG (2007) Continuous dopaminergic stimulation: is it the answer to the motor complications of levodopa? Mov Disord 22:1–9CrossRefPubMed

Olanow CW, Kieburtz K, Rascol O, Poewe W, Schapira AH, Emre M, Nissinen H, Leinonen M, Stocchi F, Stalevo Reduction in Dyskinesia Evaluation in Parkinson’s Disease (STRIDE-PD) Investigators (2013) Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson’s disease. Mov Disord 28:1064–1071CrossRef

Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, Vanagunas A, Othman AA, Widnell KL, Robieson WZ, Pritchett Y, Chatamra K, Benesh J, Lenz RA, Antonini A, LCIG Horizon Study Group (2014) Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 13:141–149CrossRefPubMed

O’Sullivan SS, Massey LA, Williams DR, Silveira-Moriyama L, Kempster PA, Holton JL, Revesz T, Lees AJ (2008) Clinical outcomes of progressive supranuclear palsy and multiple system atrophy. Brain 131(Pt 5):1362–1372CrossRefPubMed

Papa SM, Chase TN (1996) Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys. Ann Neurol 39:574–578CrossRefPubMed

Politis M, Wu K, Loane C, Brooks DJ, Kiferle L, Turkheimer FE, Bain P, Molloy S, Piccini P (2014) Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson’s disease patients. J Clin Invest 124:1340–1349CrossRefPubMedPubMedCentral

Rascol O, Fabre N (2001) Dyskinesia: l-dopa-induced and tardive dyskinesia. Clin Neuropharmacol 24:313–323CrossRefPubMed

Respondek G, Hoglinger GU (2016) The phenotypic spectrum of progressive supranuclear palsy. Parkinsonism Relat Disord 22(Suppl 1):S34–S36CrossRefPubMed

Respondek G, Levin J, Höglinger GU (2018) Progressive supranuclear palsy and multiple system atrophy: clinicopathological concepts and therapeutic challenges. Curr Opin Neurol 31:448–454PubMed

Rietdijk CD, Perez-Pardo P, Garssen J, van Wezel RJ, Kraneveld AD (2017) Exploring Braak’s hypothesis of Parkinson’s disease. Front Neurol 8:37CrossRefPubMedPubMedCentral

Sachdev PS, Brüne M (2000) Animal models of acute drug-induced akathisia—a review. Neurosci Biobehav Rev 24:269–277CrossRefPubMed

Sanci V, Houle S, DaSilva JN (2002) No change in dopamine D1 receptor in vivo binding in rats after sub-chronic haloperidol treatment. Can J Physiol Pharmacol 80:36–41CrossRefPubMed

Sawa A, Snyder SH (2002) Schizophrenia: diverse approaches to a complex disease. Science 296:692–695CrossRefPubMed

Sidhu A, Niznik HB (2000) Coupling of dopamine receptor subtypes to multiple and diverse G proteins. Int J Dev Neurosci 18:669–677CrossRefPubMed

Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, Barone P, Lang AE, Olanow CW (2010) Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 68:18–27CrossRefPubMed

Suchowersky O, Gronseth G, Perlmutter J, Reich S, Zesiewicz T, Weiner WJ (2006) Practice Parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66:976–982CrossRefPubMed

Swann NC, de Hemptinne C, Miocinovic S, Qasim S, Wang SS, Ziman N, Ostrem JL, San Luciano M, Galifianakis NB, Starr PA (2016) Gamma oscillations in the hyperkinetic state detected with chronic human brain recordings in Parkinson’s disease. J Neurosci 36:6445–6458CrossRefPubMedPubMedCentral

Trojanowski JQ, Revesz T, Neuropathology Working Group on MSA (2007) Proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy. Neuropathol Appl Neurobiol 33:615–620CrossRefPubMed

Vasta R, Nicoletti A, Mostile G, Dibilio V, Sciacca G, Contrafatto D, Cicero CE, Raciti L, Luca A, Zappia M (2017) Side effects induced by the acute levodopa challenge in Parkinson’s disease and atypical parkinsonisms. PLoS One 12:e0172145CrossRefPubMedPubMedCentral

Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN (1998) Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson’s disease. Neurology 50:1323–1326CrossRefPubMed

Vitek JL, Giroux M (2000) Physiology of hypokinetic and hyperkinetic movement disorders: model for dyskinesia. Ann Neurol 47(4 Suppl 1):S131–S140PubMed

Wenning GK, Geser F, Krismer F, Seppi K, Duerr S, Boesch S, Köllensperger M, Goebel G, Pfeiffer KP, Barone P, Pellecchia MT, Quinn NP, Koukouni V, Fowler CJ, Schrag A, Mathias CJ, Giladi N, Gurevich T, Dupont E, Ostergaard K, Nilsson CF, Widner H, Oertel W, Eggert KM, Albanese A, del Sorbo F, Tolosa E, Cardozo A, Deuschl G, Hellriegel H, Klockgether T, Dodel R, Sampaio C, Coelho M, Djaldetti R, Melamed E, Gasser T, Kamm C, Meco G, Colosimo C, Rascol O, Meissner WG, Tison F, Poewe W, European Multiple System Atrophy Study Group (2013) The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol 12:264–274CrossRefPubMedPubMedCentral

Wenning G, Trojanowski JQ, Kaufmann H, Wisniewski T, Rocca WA, Low PA (2018) Is multiple system atrophy an infectious disease? Ann Neurol 83:10–12CrossRefPubMedPubMedCentral

Williams DR, Litvan I (2013) Parkinsonian syndromes. Continuum (Minneap Minn) 19:1189–1212

Williams DR, de Silva R, Paviour DC, Pittman A, Watt HC, Kilford L, Holton JL, Revesz T, Lees AJ (2005) Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson’s syndrome and PSP-Parkinsonism. Brain 128:1247–1258CrossRefPubMed

Zhang X, Chou J, Liang J, Xiao C, Zhao Y, Sarva H, Henchcliffe C, Wang F (2019) Data-driven subtyping of Parkinson’s disease using longitudinal clinical records: a cohort study. Sci Rep 9:797CrossRefPubMedPubMedCentral

Title: Dyskinesia in multiple system atrophy and progressive supranuclear palsy
Authors: Wolfgang H. Jost
Paul Lingor
Lars Tönges
Johannes Schwarz
Carsten Buhmann
Jan Kassubek
Anette Schrag
Publication date: 01-07-2019
Publisher: Springer Vienna
Keywords: Parkinson's Disease
Atypical Parkinsonism
Levodopa
Progressive Supranuclear Palsy
Published in: Journal of Neural Transmission / Issue 7/2019
Print ISSN: 0300-9564
Electronic ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-019-02012-0

At a glance: The STEP trials

Springer Medicine

Dyskinesia in multiple system atrophy and progressive supranuclear palsy

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2019

Disease stage dependency of motor and non-motor fluctuations in Parkinson’s disease

Mild cognitive impairment in Parkinson’s disease

Sleep–wake and circadian disturbances in Parkinson disease: a short clinical guide

Hypersalivation: update of the German S2k guideline (AWMF) in short form

α-Synuclein in Parkinson’s disease: causal or bystander?

Management of delirium in Parkinson’s disease